Results 231 to 240 of about 2,878,283 (349)

Tongue Sarcoidosis: A Rare Case Report and Review of the Literature. [PDF]

open access: yesClin Case Rep
Atarbashi-Moghadam S   +4 more
europepmc   +1 more source

Tranexamic Acid Use in Hip Arthroscopy Reduces Bleeding Without Increased Risk of Major Complications: A Systematic Review

open access: yesArthroscopy, EarlyView.
Purpose To critically evaluate the impact of tranexamic acid (TXA) on hip arthroscopy outcomes, including its effects on bleeding, functional recovery, postoperative pain, complications, intraoperative visualization, and surgical efficiency. Methods A systematic review was conducted in accordance with the Preferred Reporting Items for Systematic ...
Paul B. Walker   +6 more
wiley   +1 more source

Primary Cutaneous B-Cell Lymphoma Imitating Pyoderma Gangrenosum: A Rare and Complex Diagnostic Challenge. [PDF]

open access: yesJ Clin Med
Markowska M   +6 more
europepmc   +1 more source

Local tetrahydrobiopterin administration augments reflex cutaneous vasodilation through nitric oxide-dependent mechanisms in aged human skin.

open access: yesJournal of applied physiology, 2012
A. Stanhewicz   +4 more
semanticscholar   +1 more source

A Cooperative Release of Mitochondrial DNA From Platelets and Neutrophils Drives an Interferon Signature in Systemic Sclerosis

open access: yesArthritis &Rheumatology, EarlyView.
Objective Mitochondria are organelles with a hypomethylated circular genome. Mitochondrial DNA (mtDNA) in the systemic circulation has been implicated in inflammation. This study investigates the role of circulating DNA in systemic sclerosis (SSc) and the cellular mechanisms governing its release.
Stavros Giaglis   +9 more
wiley   +1 more source

Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: A Randomized, Phase 3 Study

open access: yesArthritis &Rheumatology, EarlyView.
Objective The multinational, phase 3, double‐blind, placebo‐controlled TULIP‐SC trial evaluated the efficacy and safety of subcutaneous anifrolumab in adults who have moderate to severe systemic lupus erythematosus (SLE) activity, despite receiving standard therapy. Methods Adults with SLE received subcutaneous anifrolumab 120 mg or placebo once weekly
Susan Manzi   +12 more
wiley   +1 more source

Impact of Evolving Treatment Patterns on Interstitial Lung Disease Progression in Systemic Sclerosis Using the European Scleroderma Trials and Research Database

open access: yesArthritis &Rheumatology, EarlyView.
Objective The treatment landscape for systemic sclerosis‐associated interstitial lung disease (SSc‐ILD) has evolved with increasingly available immunosuppressive therapies (ISTs) and antifibrotic treatments. However, their real‐world use remains unclear.
Corrado Campochiaro   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy